Standout Papers

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors 2024 202653
  1. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors (2024)
    Sarah Cook, Daniel E. Meyers et al. JAMA Network Open

Immediate Impact

53 standout
Sub-graph 1 of 19

Citing Papers

Redox regulation: mechanisms, biology and therapeutic targets in diseases
2025 Standout
Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy
2025 Standout
2 intermediate papers

Works of Vishal Navani being referenced

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy
2022
Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes
2022

Author Peers

Author Last Decade Papers Cites
Vishal Navani 154 192 45 78 38 302
Alejandro Ruíz-Patiño 123 135 83 76 38 349
Johan Kurnianda 81 161 51 55 46 279
Valeria Stati 95 176 26 58 25 303
Marco Filetti 116 148 41 66 37 303
Dana Lucia Stănculeanu 50 168 43 83 46 328
Mitchell S. von Itzstein 96 205 24 37 32 317
Jo Raskin 230 172 59 108 37 370
Daniel H. Kwon 91 116 28 88 38 324
Frédéric Bigot 135 208 61 51 33 335
Kriti Mittal 132 133 102 154 28 343

All Works

Loading papers...

Rankless by CCL
2026